We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer.
- Authors
Ciunci, Christine A; Perini, Rodolfo F; Avadhani, Anjali N; Kang, Hyunseon C; Sun, Weijing; Redlinger, Maryann; Harlacker, Kathleen; Flaherty, Keith T; Giantonio, Bruce J; Rosen, Mark A; Divgi, Chaitanya R; Song, Hee Kwon; Englander, Sarah; Troxel, Andrea; Schnall, Mitchell; O'Dwyer, Peter J
- Abstract
Preclinical and clinical studies suggest mTOR (mammalian target of rapamycin) inhibitors may have metabolic and antiangiogenic effects, and synergize with epidermal growth factor pathway inhibitors. Therefore, a phase 1/pharmacodynamic trial of everolimus with cetuximab was performed.
- Publication
Cancer, 2014, Vol 120, Issue 1, p77
- ISSN
1097-0142
- Publication type
Journal Article
- DOI
10.1002/cncr.28294